Codexis Eyes 2026 Inflection with ECO Synthesis Scale-Up, $20–25M CapEx
CEO Alison Moore said RNA medicines grow 5-10% annually and Codexis expects a 2026 inflection with larger ECO Synthesis contracts, targeting a $2 billion market by 2030. The company is scaling ECO Synthesis platform to kilo scale by year-end and plans a GMP facility by end-2027 with $20-25 million.
1. Strategic Shift to RNA Medicines
Alison Moore highlighted limitations of solid-phase oligonucleotide synthesis and framed RNA medicines as a 5-10% annual growth market. She said Codexis expects customers to adopt its ECO Synthesis platform with larger contracts in 2026, targeting a $2 billion market by 2030.
2. Scaling ECO Synthesis Platform
The company is scaling ECO Synthesis from 100-gram lab runs to kilo scale by year-end and plans a GMP facility by end-2027, budgeting $20–25 million in capital. Cash runway through end-2027 will support expansion of commercial enzyme production.
3. Legacy Biocatalysis and Partnerships
Codexis’ legacy small-molecule biocatalysis business faces low single-digit growth but is underpinned by late-stage and Phase III assets, two of which recently met their goals. The company has a Merck supply assurance agreement and three CDMO partnerships to drive technology transfer and future licensing deals.